Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Intellia Therapeutics said the U.S. FDA has accepted its biologics license application for lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema (HAE) and granted priority review.
Intellia Therapeutics said the FDA accepted its biologics license application for Lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema and granted priority review.